[Erythrocyte elongation with 10% dextran 40,000: comparison of 2 substances].
A dosage-effect-study with two 10% dextrans 40,000 was carried out in 12 venous blood samples of healthy men aged from 21 to 45 years. Dextran A (trade name: Dextran 40,000 "Ebewe") and Dextran B (trade name: "Rheomacrodex") were added in dosages of 0.5 to 10 mg/ml whole blood and the elongation-index of erythrocytes at shearrate 50/sec was determined. From 1 mg up to 10 mg/ml the elongation-index in Dextran B showed a stronger decrease than in Dextran A. Under the highest dosage the difference was about 20%. So it was possible to show that in spite of identical molecular weight there are different effects on deformability of erythrocytes. This should be taken into account for parenteral treatment.
Költringer
P
P
Krankenhaus der Barmherzigen Brüder, Graz-Eggenberg.
Langsteger
W
W
Lind
P
P
Klima
G
G
Reisecker
F
F
Eber
O
O
D000328:Adult; D001783:Blood Flow Velocity / Q000187:drug effects; D003911:Dextrans / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004907:Erythrocyte Deformability / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged
D003911:Dextrans
Erythrozytenelongation unter 10% Dextran 40,000: Vergleich zweier Substanzen.